Literature DB >> 12482984

Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53.

Yoichi Ohiro1, Anny Usheva, Shinichiro Kobayashi, Shannon L Duffy, Regan Nantz, David Gius, Nobuo Horikoshi.   

Abstract

More than 50% of human cancers contain p53 gene mutations and as a result accumulate altered forms of the full-length p53 protein. Although certain tumor types expressing mutant p53 protein have a poor prognostic process, the precise role of mutant p53 protein in highly malignant tumor cells is not well defined. Some p53 mutants, but not wild-type p53, are shown here to interact with Daxx, a Fas-binding protein that activates stress-inducible kinase pathways. Interaction of Daxx with p53 is highly dependent upon the specific mutation of p53. Tumorigenic mutants of p53 bind to Daxx and inhibit Daxx-dependent activation of the apoptosis signal-regulating kinase 1 stress-inducible kinases and Jun NH(2)-terminal kinase. Mutant p53 forms complexes with Daxx in cells, and consequently, mutant p53 is able to rescue cells from Daxx-dependent inhibition of proliferation. Thus, the accumulation of mutant p53 in tumor cells may contribute to tumorigenesis by inhibiting stress-inducible kinase pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12482984      PMCID: PMC140653          DOI: 10.1128/MCB.23.1.322-334.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  66 in total

1.  TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation.

Authors:  R Perlman; W P Schiemann; M W Brooks; H F Lodish; R A Weinberg
Journal:  Nat Cell Biol       Date:  2001-08       Impact factor: 28.824

2.  The protein kinase C isoforms leading to MAP-kinase activation in CHO cells.

Authors:  K Yamaguchi; K Ogita; S Nakamura; Y Nishizuka
Journal:  Biochem Biophys Res Commun       Date:  1995-05-25       Impact factor: 3.575

Review 3.  Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells.

Authors:  M A Tainsky; F Z Bischoff; L C Strong
Journal:  Cancer Metastasis Rev       Date:  1995-03       Impact factor: 9.264

4.  Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression.

Authors:  N Horikoshi; A Usheva; J Chen; A J Levine; R Weinmann; T Shenk
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

5.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

Authors:  D Wolf; N Harris; V Rotter
Journal:  Cell       Date:  1984-08       Impact factor: 41.582

6.  p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1.

Authors:  D M Milne; L E Campbell; D G Campbell; D W Meek
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

7.  Integration of MAP kinase signal transduction pathways at the serum response element.

Authors:  A J Whitmarsh; P Shore; A D Sharrocks; R J Davis
Journal:  Science       Date:  1995-07-21       Impact factor: 47.728

8.  Transcription factor ATF2 regulation by the JNK signal transduction pathway.

Authors:  S Gupta; D Campbell; B Dérijard; R J Davis
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

Review 9.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

10.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.

Authors:  M Harvey; H Vogel; D Morris; A Bradley; A Bernstein; L A Donehower
Journal:  Nat Genet       Date:  1995-03       Impact factor: 38.330

View more
  9 in total

1.  Adenovirus type 5 early region 1B 156R protein promotes cell transformation independently of repression of p53-stimulated transcription.

Authors:  Timo Sieber; Thomas Dobner
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

2.  Daxx silencing sensitizes cells to multiple apoptotic pathways.

Authors:  Liuh-Yow Chen; J Don Chen
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

3.  Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates enhancement of p53-dependent transcription by Daxx.

Authors:  Lisa Y Zhao; April L Colosimo; Yue Liu; Yanping Wan; Daiqing Liao
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-dependent stabilization of Daxx.

Authors:  Tetsuya Kitamura; Yayoi Fukuyo; Masahiro Inoue; Nobuko T Horikoshi; Masanobu Shindoh; Buck E Rogers; Anny Usheva; Nobuo Horikoshi
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

5.  Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML.

Authors:  Eun-Joo Kim; Jong-Sup Park; Soo-Jong Um
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

6.  DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.

Authors:  Jan Brazina; Jan Svadlenka; Libor Macurek; Ladislav Andera; Zdenek Hodny; Jiri Bartek; Hana Hanzlikova
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 7.  DAXX in cancer: phenomena, processes, mechanisms and regulation.

Authors:  Iqbal Mahmud; Daiqing Liao
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

8.  Reduced DAXX Expression Is Associated with Reduced CD24 Expression in Colorectal Cancer.

Authors:  Ya-Chun Chen; Tsung-Hsien Lee; Shu-Ling Tzeng
Journal:  Cells       Date:  2019-10-12       Impact factor: 6.600

9.  Microparticles as immune regulators in infectious disease - an opinion.

Authors:  Zheng Lung Ling; Valery Combes; Georges E Grau; Nicholas J C King
Journal:  Front Immunol       Date:  2011-11-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.